Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
NCT:NCT05103566 · RECRUITING
廣告
NCT IDNCT05103566
狀態RECRUITING
開始日期2022-10-04
SponsorMassachusetts General Hospital (OTHER)
First posted
Last updated
簡要摘要
This is a single-site, single-arm, open-label pilot study assessing the safety, feasibility, and efficacy of non-invasive vagus nerve stimulation (nVNS), gammaCore, for the acute treatment of aneurysmal subarachnoid hemorrhage (SAH) subjects in a neurocritical care setting. 25 patients will be enrolled, all treated with an active device. The primary efficacy outcomes are reduced aneurysm rupture rate, reduced seizure and seizure-spectrum activity, minimized hemorrhage grades, and increased survival.
官方來源
在 ClinicalTrials.gov 上查看 →資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。